Journal Wrap | EARLY TAVR and EVOLVED; PROTECTED TAVR
The hottest research from various peer-reviewed journals – handpicked weekly by the ACC.org Editorial Board led by Kim A. Eagle, MD, MACC.
EARLY TAVR and EVOLVED: Early Intervention in Patients With Asymptomatic AS?
Two separate late-breaking trials – EARLY TAVR and EVOLVED – presented at TCT 2024 explored whether early aortic valve intervention improves outcomes in patients with asymptomatic aortic stenosis (AS). In EARLY TAVR, simultaneously published in the New England Journal of Medicine, Philippe Généreux, MD, et al., randomized 901 patients from 75 centers in the U.S. and Canada to either early TAVR with transfemoral placement of a balloon-expandable valve (n=455) or clinical surveillance (n=446). All participants had asymptomatic severe AS, 83.6% were at low surgical risk and the average age was 76 years.
Does the Benefit of CEP During TAVR Vary By Geographic Region?
While the main PROTECTED TAVR trial found no significant differences in stroke rates when cerebral embolic protection (CEP) was used during TAVR compared with TAVR alone, a post hoc analysis of the trial presented during TCT 2024 and simultaneously published in JAMA Cardiology, suggests there may be potential benefits associated with CEP use based on geographic region.
Clinical Topics: Cardiac Surgery, Congenital Heart Disease and Pediatric Cardiology, Invasive Cardiovascular Angiography and Intervention, Valvular Heart Disease, Atherosclerotic Disease (CAD/PAD), Aortic Surgery, Cardiac Surgery and CHD and Pediatrics, Cardiac Surgery and VHD, Congenital Heart Disease, CHD and Pediatrics and Interventions, Interventions and Structural Heart Disease, Interventions and Vascular Medicine
Keywords: Cardiology Magazine, ACC Publications, Transcatheter Aortic Valve Replacement, Aortic Valve Stenosis, Bicuspid Aortic Valve Disease, Peripheral Vascular Diseases, Embolic Protection Devices
